Alopecia Secondary to Endocrine Therapy in Postmenopausal Women With Breast Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01300871|
Recruitment Status : Terminated (Poor patient accrual)
First Posted : February 23, 2011
Last Update Posted : September 26, 2014
|Condition or disease|
|Study Type :||Observational|
|Estimated Enrollment :||100 participants|
|Official Title:||Alopecia Secondary to Endocrine Therapy in Postmenopausal Women With Breast Cancer|
|Study Start Date :||January 2011|
|Actual Study Completion Date :||January 2012|
Postmenopausal Women on Endocrine Therapy
Postmenopausal women with Breast Cancer that undergo Endocrine Therapy.
- Severity of Alopecia Tool (SALT) [ Time Frame: 1 year ]The proportion of postmenopausal breast cancer patients on endocrine therapy who experience grade S1 to S5 alopecia as defined by the Severity of Alopecia Tool (SALT).
- Comparison of Tamoxifen, AI or Tamoxifen plus AI [ Time Frame: 1 year ]Comparison of the proportion of postmenopausal breast cancer patients treated with Tamoxifen monotherapy, AI monotherapy, or a switch from Tamoxifen to AI who experience alopecia.
- Severity of Alopecia Tool (SALT) [ Time Frame: 1 year ]To identify the severity, or grade, of hair loss experienced by our target population. The severity of alopecia will be represented as a percentage, again in accordance with the SALT.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01300871
|Princess Margaret Hospital|
|Toronto, Ontario, Canada, M5G 3M9|
|Principal Investigator:||Lindsay Carlsson||University Health Network-Princess Margaret Hospital|